Information Provided By: 
Fly News Breaks for February 28, 2020
RHHBY, IONS
Feb 28, 2020 | 10:04 EDT
Stifel analyst Paul Matteis noted that Roche (RHHBY) presented 15-month data on HTTRx at the CHDI meeting that showed great target engagement on mutant Huntingtin and neurofilament levels that look better relative to the AAN meeting. The presentation supports HTTRx "having a shot" in phase 3, but he continues to view HTTRx as a "high risk, high potential reward" program for Ionis (IONS) and partner Roche, Matteis tells investors. He has a Hold rating on Ionis shares.
News For IONS;RHHBY From the Last 2 Days
There are no results for your query IONS;RHHBY
